Corcept Therapeutics (CORT) Key Ratios
$118.10
As on 27-Aug-2026 12:38EDT
Market cap
$13,215 Mln
Revenue (TTM)
$831 Mln
P/E Ratio
271.7
P/B Ratio
18.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 55.33 | 31.74 | 16.02 | 24.73 | 19.35 |
| EBIT | 202.72 | 44.93 | -79.11 | -37.62 | -24.42 |
| Net Profit | 235.06 | 19.89 | -58.66 | -16.60 | -10.87 |
| EPS | 219.14 | 22.02 | -62.44 | -19.97 | -11.18 |
| Book Value | -- | -- | -5.79 | 7.80 | 5.65 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 19.49 | 24.10 | 3.17 | 8.73 | 23.92 |
| Net Margin
| -- | 30.70 | 6.61 | -- | -- |
| Return on equity
| 19.87 | 21.55 | 8.11 | 15.01 | 23.56 |
| Return on Capital
| 19.77 | 21.46 | -- | 14.87 | 23.42 |
| Return on Assets
| 16.20 | 18.27 | 5.52 | 11.88 | 19.11 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
14.87
|
23.42
|
21.02
|
23.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
8.11
Lower than Peers by 10.86
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
8.11
|
15.01
|
23.56
|
21.05
|
23.11
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
5.52
Higher than Peers by 2.66
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
5.52
|
11.88
|
19.11
|
17.62
|
20.14
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
3.17
Lower than Peers by 12.65
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
3.17
|
8.73
|
23.92
|
25.82
|
28.03
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
6.61
Lower than Peers by 1.62
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
6.61
|
13.09
|
20.70
|
22.00
|
25.24
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
16.02
Higher than Peers by 7.97
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
16.02
|
0.13
|
0.40
|
0.20
|
0.10
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
-79.11
Lower than Peers by 87.37
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
-79.11
|
-58.84
|
29.65
|
10.59
|
-9.51
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-58.66
Lower than Peers by 66.39
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
-58.66
|
-28.68
|
31.65
|
4.66
|
-9.86
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
-62.44
Lower than Peers by 72.84
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
-62.44
|
-0.30
|
0.23
|
0.10
|
-0.05
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
12.98
Higher than Peers by 8.10
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
12.98
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
0.01
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.86
Higher than Peers by 1.21
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
2.86
|
2.92
|
3.35
|
4.39
|
6.89
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
2.77
Higher than Peers by 1.57
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
2.77
|
2.85
|
3.26
|
4.31
|
6.80
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
--
|
--
|
--
|
31.67
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
9.26
Lower than Peers by 12.01
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
9.26
|
7.85
|
8.60
|
11.78
|
11.66
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.84
Higher than Peers by 0.44
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
0.84
|
0.91
|
0.92
|
0.80
|
0.80
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
28.27
|
31.08
|
39.25
|
34.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
355.76
|
338.03
|
389.71
|
376.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
785.55
|
549.99
|
827.66
|
640.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
-401.52
|
-180.88
|
-398.70
|
-229.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
271.67
Higher than Peers by 234.35
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
271.67
|
41.86
|
42.72
|
33.93
|
23.30
|
|
Peer Median
|
37.31
|
--
|
--
|
--
|
--
|
Price / Book Value
18.72
Higher than Peers by 10.97
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
18.72
|
6.44
|
8.78
|
7.11
|
4.71
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
1,463.60
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
1,463.60
|
55.67
|
34.35
|
25.74
|
16.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
13,215
Higher than Peers by 10,624
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
13,215
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,591
|
--
|
--
|
--
|
--
|